Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma

Fig. 4

Combined image set shows three representative subjects with metastatic colorectal cancer (CRC). Displayed from left to right are the axial CT (upper two rows are soft-tissue window, lowest row is lung window), [18F]FDG PET, and [18F]FSPG PET images. The first subject (row a) has a rectal mass and an adjacent small perirectal lymph node, the second subject (row b) has a liver metastasis, and the third subject (row c) has pulmonary metastases on the left and an ipsilateral mediastinal lymph node metastasis. The black arrows indicate the lesions. Any unmarked uptake on the PET scans is physiologic. The lesions are seen on all modalities, and both the [18F]FDG and [18F]FSPG PET images have similar uptake across all lesions (SUV rectal mass (a) 15.8 and 12, liver lesion (b) 17.4 and 16.1, and pulmonary metastasis (c) 7.4 and 8.3, for [18F]FDG and [18F]FSPG, respectively)

Back to article page